SD BIOSENSOR INC. - Company Intelligence Brief

1. Business Overview

SD Biosensor Inc. is a Korean in-vitro diagnostic (IVD) company that experienced significant growth during the COVID-19 pandemic, primarily through diagnostic test manufacturing. Based on the dramatic financial swings in the data, the company's revenue appears heavily concentrated in rapid diagnostic testing products. The financial statements show consolidated operations (연결재무제표), indicating the company operates through multiple subsidiaries or business units.

[TRANSLATION NOTE: Company segment details are not fully disclosed in the provided financial data. Business description is inferred from publicly available information about SD Biosensor.]

2. Financial Trend

SD Biosensor's financials reveal a sharp post-pandemic correction. Revenue collapsed from KRW 2,932 billion in FY2022 to KRW 656 billion in FY2023 (-78%), with modest recovery to KRW 695 billion in FY2024 (+6%). The company swung from profitability to deep losses: net income fell from KRW +909 billion (2022) to -KRW 468 billion (2023), improving but still negative at -KRW 98 billion in 2024.

Operating margins deteriorated severely—operating loss was KRW 248 billion (2023) and KRW 54 billion (2024) versus KRW +1,147 billion operating profit (2022). Current assets declined from KRW 2,517 billion (2022) to KRW 938 billion (2024), reflecting cash burn and inventory normalization.

Debt levels remain manageable: total liabilities stood at KRW 956 billion against equity of KRW 2,932 billion (debt-to-equity ~33%) as of end-2024. Non-current liabilities increased significantly from KRW 18 billion (2022) to KRW 780 billion (2024), suggesting long-term financing or lease obligations. Retained earnings decreased from KRW 2,383 billion (2022) to KRW 1,787 billion (2024), absorbing accumulated losses.

3. Ownership Structure

The DART filing does not include detailed ownership disclosure in the provided dataset. Stated capital is KRW 62.2 billion (124.5 million shares at KRW 500 par value), unchanged between 2023-2024.

[TRANSLATION NOTE: Foreign ownership percentage and controlling shareholder information are not included in the provided financial statement extracts. This information would typically appear in separate disclosure sections of the full annual report.]

4. Key Risks

Revenue Concentration Risk: The 78% revenue decline post-pandemic suggests extreme dependence on COVID-related diagnostics with insufficient product diversification to offset the collapse in testing demand.

Profitability Recovery Uncertainty: Despite 2024 revenue stabilization, the company remains unprofitable with -KRW 98 billion net loss, indicating structural cost base misalignment with the new revenue reality. Operating leverage has not returned even with cost-cutting efforts.

5. Investment Consideration

SD Biosensor represents a speculative turnaround opportunity trading at 1.5x book value, contingent on management's ability to diversify beyond pandemic diagnostics and restore profitability in a fundamentally smaller addressable market.